At the same time, through in vitro experiments, it was found that its active components OA, TET and QUE can down-regulate the genes TGFB1, CCND1, ERBB2, and MMP9 that are highly expressed in RCC, and upregulate the genes CAT and PPARα that are poorly expressed in RCC. The gene discussed is CAT; the disease is renal cell carcinoma.